

G(W/-)(T/G)(C/G)C(T/C)(G/A)CAG-(splicing point)-G/C-exon-3' (while W is a pyrimidine, i.e., A or T) (SEQ ID NO:27), e.g., 5'-GATATCCTGCAG G-3' (SEQ ID NO:28), 5'-GGCTGCAG G-3', 5'-CCACAG C-3' and so on. The branch point is an "A" residue located within a sequence homologous to 5'-TACT(A/T)A*(C/T)(-/C)-3' (while the symbol "*" marks the branch site), e.g., 5'-TACTAAC-3', 5'-TACTTATC-3' and so on. The poly-pyrimidine tract is a high T and/or C content oligonucleotide sequence homologous to 5'-(TY)_m(C/-)(T)_nC(C/-)-3' (SEQ ID NO:31) or 5'-(TC)_nNCTAG(G/-)-3' (while Y is a C or T) (SEQ ID NO:32). The symbols "m" and "n" indicate the numbers of repeats, preferably, m = 1~3 and n = 7~12. For all the above splicing components, the deoxythymidine (T) in a DNA template is replaced by uridine (U) after transcription.


REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendment in the specification merely inserts the paper copy of the Sequence Listing, the corresponding sequence identifiers, and a description of the exemplary sequence in Fig. 1 in the specification. No new matter has been added.

Respectfully submitted,

HOGAN & HARTSON L.L.P.

Dated: June 18, 2004

By: 
Olga Berson
Reg. No. 55,001

Biltmore Tower
500 S. Grand Avenue, Suite 1900
Los Angeles, CA 90017
Telephone: (213) 337-6700
Fax: (213) 337-6701